Studies included
| Reference, year . | Study name . | Regimen used . | Total, N . | Elderly, % . |
|---|---|---|---|---|
| Peterson et al,16 2003 | CALGB7951 | CTX vs CHOP-B | 189 | 7.4 |
| Hochster et al,17 2009 | E1496 | MR vs Obs after CVP | 285 | 15.1 |
| Hagenbeek et al,18 2006 | EORTC20921 | Fludarabine vs CVP | 231 | 6.9 |
| Salles et al,19 2008 | FL2000 | CHVP+I vs R-CHVP+I | 358 | 11.2 |
| Solal-Celigny et al,20 1993; Solal-Celigny et al,21 1998; Bachy et al,22 2010 | GELF862 | CHVP vs CHVP+I | 242 | 0.8 |
| Ladetto et al,23 2008 | GITMO | R-HDS vs R-CHOP | 134 | 0.7 |
| Nickenig et al,24 2006 | GLSG1996 | CHOP vs MCP | 536 | 8.0 |
| Hiddemann et al,25 2005 | GLSG2000 | CHOP vs R-CHOP | 1040 | 8.6 |
| Salles et al,26 2008 | GOELAMS052 | CHVP vs FM | 85 | 17.6 |
| Marcus et al,27 2008 | M39021 | CVP vs CVP+R | 322 | 7.5 |
| Herold et al,28 2007 | OSHO39 | MCP vs R-MCP | 207 | 5.3 |
| Kimby et al,29 2015 | ML16865 | R vs R+IFN | 228 | 11.8 |
| Vitolo et al,30 2013 | ML17638 | R vs Obs after R-FND | 234 | 17.5 |
| Morschhauser et al,31 2008 | FIT | 90Y-ibritumomab tiuxetan vs Obs for consolidation therapy | 414 | 5.1 |
| Herold et al,32 2006 | OSHO19 | BOP vs CVP | 75 | 12.0 |
| Salles et al,33 2011 | PRIMA | R vs Obs maintenance | 1018 | 9.8 |
| Ghielmini et al,34 2004; Martinelli et al,35 2010 | SAKK35/98 | Therapy vs Obs after R | 45 | 8.9 |
| Rummel et al,36 2013 | NHL12003 | B-R vs R-CHOP | 279 | 15.1 |
| Reference, year . | Study name . | Regimen used . | Total, N . | Elderly, % . |
|---|---|---|---|---|
| Peterson et al,16 2003 | CALGB7951 | CTX vs CHOP-B | 189 | 7.4 |
| Hochster et al,17 2009 | E1496 | MR vs Obs after CVP | 285 | 15.1 |
| Hagenbeek et al,18 2006 | EORTC20921 | Fludarabine vs CVP | 231 | 6.9 |
| Salles et al,19 2008 | FL2000 | CHVP+I vs R-CHVP+I | 358 | 11.2 |
| Solal-Celigny et al,20 1993; Solal-Celigny et al,21 1998; Bachy et al,22 2010 | GELF862 | CHVP vs CHVP+I | 242 | 0.8 |
| Ladetto et al,23 2008 | GITMO | R-HDS vs R-CHOP | 134 | 0.7 |
| Nickenig et al,24 2006 | GLSG1996 | CHOP vs MCP | 536 | 8.0 |
| Hiddemann et al,25 2005 | GLSG2000 | CHOP vs R-CHOP | 1040 | 8.6 |
| Salles et al,26 2008 | GOELAMS052 | CHVP vs FM | 85 | 17.6 |
| Marcus et al,27 2008 | M39021 | CVP vs CVP+R | 322 | 7.5 |
| Herold et al,28 2007 | OSHO39 | MCP vs R-MCP | 207 | 5.3 |
| Kimby et al,29 2015 | ML16865 | R vs R+IFN | 228 | 11.8 |
| Vitolo et al,30 2013 | ML17638 | R vs Obs after R-FND | 234 | 17.5 |
| Morschhauser et al,31 2008 | FIT | 90Y-ibritumomab tiuxetan vs Obs for consolidation therapy | 414 | 5.1 |
| Herold et al,32 2006 | OSHO19 | BOP vs CVP | 75 | 12.0 |
| Salles et al,33 2011 | PRIMA | R vs Obs maintenance | 1018 | 9.8 |
| Ghielmini et al,34 2004; Martinelli et al,35 2010 | SAKK35/98 | Therapy vs Obs after R | 45 | 8.9 |
| Rummel et al,36 2013 | NHL12003 | B-R vs R-CHOP | 279 | 15.1 |
BOP, bleomycin, vincristine, and cisplatin; B-R, bendamustine and rituximab; CALGB, Cancer and Leukemia Group B; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP-B, cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin; CHVP, cyclophosphamide, Adriamycin (doxorubicin), etoposide, and prednisolone; CHVP+I, cyclophosphamide, Adriamycin, etoposide, and prednisolone plus interferon; CTX, cyclophosphamide; CVP, cyclophosphamide, vincristine, and prednisone; CVP+R, cyclophosphamide, vincristine, and prednisone plus rituximab; EORTC, European Organisation for Research and Treatment of Cancer; FIT, First-Line Indolent Trial; FL, Follicular Lymphoma; FM, fludarabine and mitoxantrone; GELF, Groupe d’Etude Lymphomes Folliculaire; GITMO, Gruppo Italiano Trapianti di Midollo Osseo; GLSG, German Low Grade Lymphoma Study Group; GOELAMS, Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang; MCP, mitoxantrone, chlorambucil, and prednisolone; MR, maintenance rituximab; NHL, Non-Hodgkin Lymphoma; Obs, observation; OSHO, Ostdeutsche Studiengruppe Haematologie/Oncologie; PRIMA, Primary Rituximab and Maintenance; R, rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHVP + I, rituximab, cyclophosphamide, Adriamycin, etoposide, and prednisolone plus interferon; R-FND, rituximab, fludarabine, mitoxantrone, and dexamethasone; R-HDS, high-dose sequential chemotherapy with rituximab; R+IFN, rituximab plus interferon; R-MCP, rituximab, mitoxantrone, chlorambucil, and prednisolone; SAKK, Swiss Group for Clinical Cancer Research.